MedTrace Logo

Efficacy and Safety of AP Collagen Peptide on the Skin

NCT05059197 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2021-11-11

No results posted yet for this study

Summary

This double-blinded, randomized, placebo-controlled study aimed to evaluate the efficacy and safety of AP collagen peptides (APCP) containing 3% Glycine-Proline-Hydroxyproline (GPH) on improving skin health. Subjects with dried skin were randomly assigned to receive placebo or APCP once daily for 12 weeks.

Conditions

  • Dry Skin

Interventions

DIETARY_SUPPLEMENT

AP collagen peptide

Health functional food

DIETARY_SUPPLEMENT

Placebo

placebo

Sponsors & Collaborators

  • Amorepacific Corporation

    lead INDUSTRY

Principal Investigators

  • Hae Kwang Lee, PhD · P&K Skin Research Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2021-09-30
Completion
2021-10-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059197 on ClinicalTrials.gov